Cempra to Present at Upcoming Investor Conferences CHAPEL

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
97
Cempra to Present at Upcoming Investor Conferences

CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP ), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences.

  • Leerink Partners 6 th Annual Global Healthcare Conference, Waldorf Astoria, New York, February 15, 2017 at 10:00 a.m. ET  
  • Cowen and Company 37 th Annual Healthcare Conference, Marriott Copley Place, Boston, March 6, 2017 at 4:00 p.m. ET  
  • Raymond James 38 th Annual Institutional Investors Conference, JW Marriott Grande Lakes, Orlando, March 7, 2017 at 10:30 a.m. ET

A live audio webcast and archive of the presentations will be available on the company website at http://investor.cempra.com/events.cfm . Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra’s two lead product candidates are currently in advanced clinical development. Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community-acquired bacterial pneumonia.  Cempra is currently seeking approval for both intravenous and oral capsule formulations from the U.S. Food and Drug Administration and the European Medicines Agency. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use and has commenced enrollment in a global Phase 2/3 trial to evaluate the safety and efficacy of solithromycin versus standard of care antibiotics in children and adolescents from two months to 17 years of age. Fusidic acid is Cempra's second product candidate, which has completed enrollment of an initial Phase 3 trial comparing fusidic acid to linezolid in patients with acute bacterial skin and skin structure infections. Cempra also has an ongoing exploratory study of fusidic acid for chronic oral treatment of refractory infections in bones and joints.

Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is also studying solithromycin for ophthalmic conditions and has synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com .

Company Contact: John Bluth Cempra, Inc. +1 984 209 4534 jbluth@cempra.com  Investor Contact: Robert Uhl Westwicke Partners, LLC +1 858 356 5932 robert.uhl@westwicke.com  Media Contact:  Melyssa Weible Elixir Health PR +1 201 723 5805 mweible@elixirhealthpr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 8

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 2

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 6

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 4

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 5

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 2

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting MEXC and Aptos Partnership Unveils Major Prize Events

Updated Category News Views 69

MEXC and Aptos Collaboration Recently, MEXC has announced an exciting collaboration with Aptos, creating a series of events centered around Aptos' native token, APT. This partnership offers a total prize pool of an astounding 1.5 million USDT, which is sure to catch the attention of many crypto enthusiasts and traders. Overview of the Events The events are designed to...

Continue Reading
Jim Cramer's Insights on Shopify and CoreWeave's AI Strategy

Updated Category News Views 177

Jim Cramer's Perspective on Shopify's Growth Potential Recently, renowned financial commentator Jim Cramer expressed optimism regarding Shopify Inc. (NASDAQ: SHOP), suggesting that the company is poised for significant growth. Cramer shared these insights on CNBC's "Mad Money", emphasizing that Shopify's innovative capabilities and expanding market share indicate a...

Continue Reading
Citrin Cooperman Expands with Clearview Group Acquisition

Updated Category News Views 174

Citrin Cooperman Expands Its Reach Citrin Cooperman has made significant strides in enhancing its service offerings with the recent announcement of its agreement to acquire the Clearview Group. This acquisition marks a pivotal moment for Citrin Cooperman as it seeks to strengthen its presence in the Mid-Atlantic region. Clearview Group is a well-respected management...

Continue Reading
Amazon's Key Earnings Report: What Investors Should Know

Updated Category News Views 87

The Importance of Amazon's Upcoming Earnings Report Shares of tech giant Amazon.com (NASDAQ: AMZN) are currently hovering just above $230 as the company prepares for its first earnings report of the year. This report holds substantial weight as it comes after a period where Amazon has struggled to break through its record highs from last November. The stock is showing...

Continue Reading
Aquablation Therapy Triumphs at EAU 2025: A New Era in BPH Treatment

Updated Category News Views 469

Aquablation Therapy Triumphs at EAU 2025: A New Era in BPH Treatment SAN JOSE, Calif. – PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is thrilled to share groundbreaking results from the WATER III trial, an independent study that puts Aquablation therapy at the forefront of treatment for benign prostatic hyperplasia (BPH). At the recent European Association of Urology...

Continue Reading